212 Users Online
Radiation Pneumonitis Treatment Market Segmented By Risk of Development such as Patient Related Factors and Treatment Related Factors having 4D CT ventilation imaging, Imaging Based Biomarkers: Pre-Treatment FDG and NTCP Modeling (Risk Assessment) Technology
According to the latest research by PMR, Radiation Pneumonitis Treatment is set to witness a 4.2% growth during the year 2021-2031. Radiation pneumonitis is an inflammation of the lung tissue induced by radiotherapy, thus affecting its therapeutic ratio. The major factor involving the occurrence of radiation pneumonitis include the size of the area receiving radiation treatment.
The demand for radiation pneumonitis treatment is set to increase over the forecast period. This is due to the high incidence of occurrence of symptomatic radiation pneumonitis with incidence rate up to 40% in most patients receiving radiotherapy, as according to the data published by the Journal of European Society for Therapeutic Radiology and Oncology.
FREE Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
The demand for radiation pneumonitis treatment is largely based on the risk of development of radiation pneumonitis due to patient related factors as well as treatment related factors. The patient related factors, such as patient age, gender, smoking status, performance status and underlying pulmonary conditions increase the chances of developing radiation pneumonitis.
These factors extend support to the growth in demand for radiation pneumonitis treatment. Essentially, treatment factors such as chemotherapy and immunotherapy have highest risk associated with radiation pneumonitis. These factors propel the need for radiation pneumonitis treatment.
The advancements in the understanding of molecular mechanisms involving the injury of tissues and the novel methodologies for the prevention and treatment of radiation pneumonitis has led to a drive in demand for radiation pneumonitis treatment.
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized VersionInitially, radiation pneumonitis treatment was done by the use of cortecosteriods. The factors introduced for the management of radiation pneumonitis such as the application of therapies targeting free radical production are the most augmentative factors for radiation pneumonitis treatment.
Additionally, the assessment of treatment factors involving the targeting of cytokine and Growth Factor Expression after radiation will improve the growth of demand in radiation pneumonitis treatment prior to successful clinical models. The adoption of Intensity-modulated Therapy also associates with lower rates of radiation pneumonitis and acts as a supplementary factor for growth in radiation pneumonitis treatment.
According to the Future Oncology journal data study for the year 2019, the incidence of radiation pneumonitis in the U.S. population accounted for over 12.4% for patients with Stage III non-small-cell lung cancer. This incidence is also associated with the higher healthcare cost of treatment of radiation pneumonitis in the U.S. Government support with programs such as Medicaid have positively influenced the adoption of radiation pneumonitis treatment in the country.
There is an extensive amount of research studies involving the incidence of radiation pneumonitis and its management and treatment in Canada. The institutes such as the Canadian Cancer Society offer specialized treatment plans for the management of radiation pneumonitis in addition to offering knowledge and awareness based on procedures involving radiation therapy.
Sales Team
Client Partner
According to a recent study review by BMC Pulmonary Medicine, patient related habits with regard to smoking can play an evidenced impact on lung tissue post radiation therapy. In the U.K., over 6.7% of patients with Stereotactic Ablative Radiotherapy developed radiation pneumonitis in a 2018 study.
The relation between smoking and development of radiation pneumonitis in the region of Europe has impacted the evaluation of radiation pneumonitis treatment for post-radiation therapy.
The key companies working in radiation therapy and solutions for radiation pneumonitis treatment and management are
By Risk of Development
By Technology
By End User
By Region
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company.
